Novarex

At a glance

Novarex filed 49 disclosures in the last 12 months, including 19 insider, 8 5% holder, 3 buyback and 1 issuance. The most recent key filing was on Oct 20: A major holder's stake rose from 32.02% to 32.02% (gift).

Revenue for 2025 was ₩404B, up 35.8% on 2024. Operating margin was 10.6% against 7.8% a year earlier. Debt was 41% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩223B and operating profit of ₩25.1B.

The 2025 annual report lists 505 employees with an average tenure of 4.4 years and average pay of ₩58.7M, #1226 of 2,191 listed companies by average pay. Its 6 directors and auditors were paid ₩352M each on average. It paid ₩400 per common share in cash dividends, against ₩200 a year earlier (+100%). 권석형 and related parties held 31.10% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 1 cut a stake; the largest stake reported was 32.02% on Oct 20.

From the 2025 annual report

Staff: 505 (287 men, 218 women), of whom 22 on fixed-term contracts. Total pay for the year: ₩27.6B. Directors and auditors: 6, paid ₩2.1B in total.

Dividends (common shares)

Largest shareholder

권석형 holds 12.50%; with 8 related parties the group holds 31.10% of common shares at year end (from 31.00% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Rankings: Dividend growth #93 of 1,046 · Revenue growth #97 of 1,376

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports